What should be addressed in the nonclinical pharmacokinetics section?

• A. Absorption and local and systemic bioavailability
• B. Packaging design
• C. Labeling equivalence
• D. Marketing plan

Answer: (A)

Nonclinical pharmacokinetics focuses on how a compound is absorbed, distributed, metabolized, and excreted in preclinical studies, and on the fraction that reaches the systemic circulation after non-intravenous administration. Therefore, what should be addressed is absorption and local and systemic bioavailability, because you need to understand how much of the drug becomes available at the site of action and in the bloodstream to inform exposure, safety margins, and dose selection for clinical trials. Local bioavailability matters for topical or inhaled formulations and reflects amount available at the site of administration, while systemic bioavailability indicates the fraction that enters circulation. Packaging design, labeling equivalence, and marketing plan are not part of nonclinical pharmacokinetics; they relate to formulation packaging, regulatory labeling, and commercialization.